InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,442.00
(
2.14%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,953.72
(
0.10%
)
Post# of 245499
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mick

Send PM Follow Ignore
Followers 3156
Posts 961240
Boards Moderated 205
Alias Born 09/04/2000

mick

Member Level

Re: $Pistol Pete$ post# 139696

Wednesday, 10/11/2017 3:09:18 PM

Wednesday, October 11, 2017 3:09:18 PM

Post# of 245499
Merck & Co Buys Into KalVista For $760 Million For Diabetic Eye Disease

Merck & Co, just partnered with Kalvista for its plasma Kallikrien inhibitors. Merck is set to pay $37 million upfront for an option to purchase KalVista’s program in diabetic macular edema, a buildup of fluid in the eye can result in loss of sight, and has also agreed to give up to $715 million in milestones also including royalties if it leads to a commercial product. It’s also paying $9 million for a 9.9% stake in the biotech company.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up